Compare FMC Corp (FMC) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs GE HealthCare Technologies Inc. Common Stock — how do they compare? FMC Corp trades at $8.05 (market cap $1.29B), while GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 24.1× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.85%). Which is the better fit depends on your goals.
| FMC | GEHC | |
|---|---|---|
Market Cap | $1.29B | $31.07B |
Volume | 3,528,603 | 3,443,020 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $88.16 |
52-Week Low | $8.09 | $59.48 |
Typical Hold Time | 68 Days | — |
Enterprise Value | $5.10B | $39.53B |
Dividend Yield | 3.85% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.09, down 2.76% on the day, with a bearish technical signal and weak fundamentals including a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent earnings show mixed results with Q2 2026 beating estimates, but revenue has declined from $5.8B in 2022 to $3.47B in 2025. Positive developments include a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group, yet cash flow from operations remains negative.
The outlook is cautious; while analyst consensus is a buy with a $14.20 price target, high debt and cyclical industry headwinds pose significant risks. Aggressive deleveraging efforts may improve financial stability, but persistent revenue declines and negative profitability underscore substantial challenges for near-term recovery.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
